JPMorgan lowered the firm’s price target on Xencor (XNCR) to $18 from $20 and keeps an Overweight rating on the shares following the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor Reports Improved Q3 2025 Financial Results
- Xencor’s Promising Clinical Updates and Strong Efficacy Support Buy Rating
- Promising Developments in Xencor’s Oncology and Autoimmune Pipelines Justify Buy Rating
- Xencor reports Q3 EPS (8c), consensus (70c)
- Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner